Humacyte is trading 5.8% down now at $0.57 after investors continued reacting to its August 12 second-quarter report, which showed revenue of $406,000 versus approximately $1.11 million expected.
- Reported a $36.8 million net loss.
- Shares remain below Nasdaq’s $1 minimum-bid requirement, with until January 27, 2027, to regain compliance.
- Positive dialysis trial results have not offset near-term commercial and listing concerns.